Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 9 of 9
Full-Text Articles in Medicine and Health Sciences
Can Covid-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading To?, Altijana Hromić-Jahjefendić, Debmalya Barh, Vladimir N. Uversky, Alaa A. A. Aljabali, Murtaza M. Tambuwala, Fuad M. Alzahrani, Saleh Alshammeri, Kenneth Lundstrom
Can Covid-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading To?, Altijana Hromić-Jahjefendić, Debmalya Barh, Vladimir N. Uversky, Alaa A. A. Aljabali, Murtaza M. Tambuwala, Fuad M. Alzahrani, Saleh Alshammeri, Kenneth Lundstrom
Molecular Medicine Faculty Publications
According to the WHO, as of January 2023, more than 850 million cases and over 6.6 million deaths from COVID-19 have been reported worldwide. Currently, the death rate has been reduced due to the decreased pathogenicity of new SARS-CoV-2 variants, but the major factor in the reduced death rates is the administration of more than 12.8 billion vaccine doses globally. While the COVID-19 vaccines are saving lives, serious side effects have been reported after vaccinations for several premature non-communicable diseases (NCDs). However, the reported adverse events are low in number. The scientific community must investigate the entire spectrum of COVID-19-vaccine-induced …
Sars-Cov-2 Intermittent Virulence As A Result Of Natural Selection, Alberto Rubio-Casillas, Elrashdy M. Redwan, Vladimir N. Uversky
Sars-Cov-2 Intermittent Virulence As A Result Of Natural Selection, Alberto Rubio-Casillas, Elrashdy M. Redwan, Vladimir N. Uversky
Molecular Medicine Faculty Publications
For the first time in history, we have witnessed the origin and development of a pandemic. To handle the accelerated accumulation of viral mutations and to comprehend the virus’ evolutionary adaptation in humans, an unparalleled program of genetic sequencing and monitoring of SARS-CoV-2 variants has been undertaken. Several scientists have theorized that, with the Omicron surge producing a more contagious but less severe disease, the end of COVID-19 is near. However, by analyzing the behavior shown by this virus for 2 years, we have noted that pandemic viruses do not always show decreased virulence. Instead, it appears there is an …
Early Taurine Administration As A Means For Halting The Cytokine Storm Progression In Covid-19 Patients, Alberto Rubio-Casillas, Ramesh C. Gupta, Elrashdy M. Redwan, Vladimir N. Uversky, Raied A. Badierah
Early Taurine Administration As A Means For Halting The Cytokine Storm Progression In Covid-19 Patients, Alberto Rubio-Casillas, Ramesh C. Gupta, Elrashdy M. Redwan, Vladimir N. Uversky, Raied A. Badierah
Molecular Medicine Faculty Publications
Around the world, more than 6.2 million individuals have died as a result of coronavirus disease 2019 (COVID-19). According to a recent survey conducted among immunologists, epidemiologists, and virologists, this disease is expected to become endemic. This implies that the disease could have a continuous presence and/or normal frequency in the population. Pharmacological interventions to prevent infection, as well as to treat the patients at an early phase of illness to avoid hospitalization are essential additions to the vaccines. Taurine is known to inhibit the generation of all inflammatory mediators linked to the cytokine storm. It can also protect against …
Sars-Cov-2: A Master Of Immune Evasion, Alberto Rubio-Casillas, Elrashdy M. Redwan, Vladimir N. Uversky
Sars-Cov-2: A Master Of Immune Evasion, Alberto Rubio-Casillas, Elrashdy M. Redwan, Vladimir N. Uversky
Molecular Medicine Faculty Publications
Viruses and their hosts have coevolved for a long time. This coevolution places both the pathogen and the human immune system under selective pressure; on the one hand, the immune system has evolved to combat viruses and virally infected cells, while viruses have developed sophisticated mechanisms to escape recognition and destruction by the immune system. SARS-CoV-2, the pathogen that is causing the current COVID-19 pandemic, has shown a remarkable ability to escape antibody neutralization, putting vaccine efficacy at risk. One of the virus’s immune evasion strategies is mitochondrial sabotage: by causing reactive oxygen species (ROS) production, mitochondrial physiology is impaired, …
Would New Sars-Cov-2 Variants Change The War Against Covid-19?, Elrashdy M. Redwan, Fatma Elrashdy, Alaa A.A. Aljabali, Wagner Baetas-Da-Cruz, Debmalya Barh, Adam M. Brufsky, Sk. Sarif Hassan, Kenneth Lundstrom, Ángel Serrano-Aroca, Kazuo Takayama, Murtaza M. Tambuwala, Bruce D. Uhal, Vladimir N. Uversky
Would New Sars-Cov-2 Variants Change The War Against Covid-19?, Elrashdy M. Redwan, Fatma Elrashdy, Alaa A.A. Aljabali, Wagner Baetas-Da-Cruz, Debmalya Barh, Adam M. Brufsky, Sk. Sarif Hassan, Kenneth Lundstrom, Ángel Serrano-Aroca, Kazuo Takayama, Murtaza M. Tambuwala, Bruce D. Uhal, Vladimir N. Uversky
Molecular Medicine Faculty Publications
The scientific, private, and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are: (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both cases of natural infections and post-vaccinations? …
Potential Molecular Mechanisms Of Rare Anti-Tumor Immune Response By Sars-Cov-2 In Isolated Cases Of Lymphomas, Debmalya Barh, Sandeep Tiwary, Lucas Gabriel Rodrigues Gomes, Marianna E. Weener, Khalid J. Alzahrani, Khalaf F. Alsharif, Alaa A. A. Aljabali, Murtaza M. Tambuwala, Kenneth Lundstrom, Sk. Sarif Hassan, Ángel Serrano-Aroca, Kazuo Takayama, Preetam Ghosh, Elrashdy M. Redwan, Bruno Silva Andrade, Siomar De Castro Soares, Vasco Azevedo, Vladimir N. Uversky
Potential Molecular Mechanisms Of Rare Anti-Tumor Immune Response By Sars-Cov-2 In Isolated Cases Of Lymphomas, Debmalya Barh, Sandeep Tiwary, Lucas Gabriel Rodrigues Gomes, Marianna E. Weener, Khalid J. Alzahrani, Khalaf F. Alsharif, Alaa A. A. Aljabali, Murtaza M. Tambuwala, Kenneth Lundstrom, Sk. Sarif Hassan, Ángel Serrano-Aroca, Kazuo Takayama, Preetam Ghosh, Elrashdy M. Redwan, Bruno Silva Andrade, Siomar De Castro Soares, Vasco Azevedo, Vladimir N. Uversky
Molecular Medicine Faculty Publications
Recently, two cases of complete remission of classical Hodgkin lymphoma (cHL) and follicular lymphoma (FL) after SARS-CoV-2 infection were reported. However, the precise molecular mechanism of this rare event is yet to be understood. Here, we hypothesize a potential anti-tumor immune response of SARS-CoV-2 and based on a computational approach show that: (i) SARS-CoV-2 Spike-RBD may bind to the extracellular domains of CD15, CD27, CD45, and CD152 receptors of cHL or FL and may directly inhibit cell proliferation. (ii) Alternately, upon internalization after binding to these CD molecules, the SARS-CoV-2 membrane (M) protein and ORF3a may bind to gamma-tubulin complex …
Covid-19 Vaccines And Thrombosis—Roadblock Or Dead-End Street?, Kenneth Lundstrom, Debmalya Barh, Bruce D. Uhal, Kazuo Takayama, Alaa A. A. Aljabali, Tarek Mohamed Abd El-Aziz, Amos Lal, Elrashdy M. Redwan, Parise Adadi, Gaurav Chauhan, Samendra P. Sherchan, Gajendra Kumar Azad, Nima Rezaei, Ángel Serrano-Aroca, Nicolas G. Bazan, Sk. Sarif Hassan, Pritam Kumar Panda, Pabitra Pal Choudhury, Damiano Pizzol, Ramesh Kandimalla, Wagner Baetas-Da-Cruz, Yogendra Kumar Mishra, Giorgio Palù, Adam M. Brufsky, Murtaza M. Tambuwala, Vladimir N. Uversky
Covid-19 Vaccines And Thrombosis—Roadblock Or Dead-End Street?, Kenneth Lundstrom, Debmalya Barh, Bruce D. Uhal, Kazuo Takayama, Alaa A. A. Aljabali, Tarek Mohamed Abd El-Aziz, Amos Lal, Elrashdy M. Redwan, Parise Adadi, Gaurav Chauhan, Samendra P. Sherchan, Gajendra Kumar Azad, Nima Rezaei, Ángel Serrano-Aroca, Nicolas G. Bazan, Sk. Sarif Hassan, Pritam Kumar Panda, Pabitra Pal Choudhury, Damiano Pizzol, Ramesh Kandimalla, Wagner Baetas-Da-Cruz, Yogendra Kumar Mishra, Giorgio Palù, Adam M. Brufsky, Murtaza M. Tambuwala, Vladimir N. Uversky
Molecular Medicine Faculty Publications
Two adenovirus-based vaccines, ChAdOx1 nCoV-19 and Ad26.COV2.S, and two mRNA-based vaccines, BNT162b2 and mRNA.1273, have been approved by the European Medicines Agency (EMA), and are invaluable in preventing and reducing the incidence of coronavirus disease-2019 (COVID-19). Recent reports have pointed to thrombosis with associated thrombocytopenia as an adverse effect occurring at a low frequency in some individuals after vaccination. The causes of such events may be related to SARS-CoV-2 spike protein interactions with different C-type lectin receptors, heparan sulfate proteoglycans (HSPGs) and the CD147 receptor, or to different soluble splice variants of the spike protein, adenovirus vector interactions with the …
On The Safety Of The Covid-19 Convalescent Plasma Treatment: Thrombotic And Thromboembolic Concerns, Fatma Elrashdy, Elrashdy M. Redwan, Vladimir N. Uversky
On The Safety Of The Covid-19 Convalescent Plasma Treatment: Thrombotic And Thromboembolic Concerns, Fatma Elrashdy, Elrashdy M. Redwan, Vladimir N. Uversky
Molecular Medicine Faculty Publications
Recently, it was reported that near-sourced COVID-19 convalescent plasma (CP) is more efficient than distantly sourced CP. What was left behind in this analysis is the investigation of the possible causes of mortality associated with the CP transfusion itself. Knowing this information is important for determining whether not receiving CP of near source is the main cause of high rate of death in the group of patients who received distantly sourced CP. We argue that the thrombotic and thromboembolic events may act as risk factors for adverse complications and death associated with CP transfusion. Therefore, they have to be considered …
Why Covid-19 Transmission Is More Efficient And Aggressive Than Viral Transmission In Previous Coronavirus Epidemics?, Fatma Elrashdy, Elrashdy M. Redwan, Vladimir N. Uversky
Why Covid-19 Transmission Is More Efficient And Aggressive Than Viral Transmission In Previous Coronavirus Epidemics?, Fatma Elrashdy, Elrashdy M. Redwan, Vladimir N. Uversky
Molecular Medicine Faculty Publications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a pandemic of coronavirus disease 2019 (COVID-19). The worldwide transmission of COVID-19 from human to human is spreading like wildfire, affecting almost every country in the world. In the past 100 years, the globe did not face a microbial pandemic similar in scale to COVID-19. Taken together, both previous outbreaks of other members of the coronavirus family (severe acute respiratory syndrome (SARS-CoV) and middle east respiratory syndrome (MERS-CoV)) did not produce even 1% of the global harm already inflicted by COVID-19. There are also four other CoVs capable of infecting humans …